Compare Paychex, Inc. (PAYX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs Viatris Inc — how do they compare? Paychex, Inc. trades at $111.32 (market cap $39.82B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Paychex, Inc. is the larger of the two by market cap, and Paychex, Inc. pays the higher dividend (4.25%). Which is the better fit depends on your goals.
| PAYX | VTRS | |
|---|---|---|
Market Cap | $39.82B | $20.50B |
Sector | Industrials | Health |
52-Week High | $147.99 | $17.59 |
52-Week Low | $85.57 | $8.74 |
Enterprise Value | $43.31B | $32.71B |
Dividend Yield | 4.25% | 2.73% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
